P-61 LIVER TRANSPLANTATION IN HEPATOCARCINOMA: SURVIVAL AND RECURRENCE IN TRANSPLANTED PATIENTS WITH HEPATOCARCINOMA

• Main Authors: Daniela García, Fodda Chelech, Andrea Jiménez, Alvaro Urzúa, Maximo Cattaneo, Juan Pablo Roblero, Alexis Iracheta, Jaime Poniachik
• Format: Article
• Language: English
• Published: Elsevier 2021-09-01
• Series: Annals of Hepatology
• Online Access: http://www.sciencedirect.com/science/article/pii/S166526812100123X

Introduction: Hepatocellular carcinoma (HCC) is the most common malignant liver tumor. Liver transplantation (LT) is considered potentially curative, achieving a survival of 70% at 5 years and a tumor recurrence <15% when the Milan criteria are used. Objectives: To study the frequency of tumor recurrence in transplant patients with HCC and to evaluate survival at 1 and 5 years. Methods: Retrospective study of 79 transplant patients with HCC, with a median of 62 years, 69% male. Clinical characteristics, pre LT and post LT Milan criteria, post LT tumor recurrence, and 1 and 5 year survival were analyzed. Statistical analysis with Kaplan Meier. Results: The etiology of cirrhosis was 35% NASH, 15% OH, 12% HCV, with an average MELD of 17%, Child A 17%, B 45% and C 38%. 92% met the pre-LT Milan criteria and 63% according to the findings of the explant, of the latter, 16% (8/50) presented microvascular invasion. Overall survival at 1 and 5 years was 96% and 75%, respectively. HCC recurrence occurred in 10% (8/79), 7/8 outside Milan in the explant, with an average recurrence of 8 months and a surplus of 18 months. Conclusion: HCC recurrence in this study was within the values ​​described in the literature, as well as short and long term survival. LT is an excellent treatment for the management of patients with HCC, achieving good survival results when they are within the Milan criteria.